How Much Does Accutane (Isotretinoin) Cost in Hawaii in 2026?

Retail Pricing for Isotretinoin Across Hawaii

The average cash price for a 30-day supply of generic isotretinoin at Hawaii retail pharmacies sits around $350 in 2026. That figure can vary by $50 to $100 depending on the specific generic manufacturer, capsule strength, and pharmacy location. Oahu pharmacies in urban Honolulu tend to cluster near the state average, while pharmacies on neighbor islands like Maui, Kauai, and the Big Island may charge slightly more due to shipping and distribution overhead.

Brand-name Accutane carries a manufacturer list price near $1,200 per month. Almost no one pays that figure. Since Roche discontinued brand Accutane in 2009, several generic versions have entered the market: Amnesteem, Claravis, Myorisan, Zenatane, and Absorica. Absorica is the only formulation with FDA-approved bioavailability data showing it can be taken without food, and it typically costs more than standard generics.

A 5-to-6-month treatment course at the standard dose of 0.5 to 1 mg/kg/day means total out-of-pocket costs for uninsured patients in Hawaii range from $1,750 to $2,100 at the average cash price. Dose matters here. A 70 kg patient prescribed 40 mg daily will pay less per month than the same patient on 70 mg daily, because capsule count and strength directly affect price. The original key trial by Strauss et al. (1984) established the 0.5 to 1 mg/kg dosing range that remains the standard today, with a cumulative target of 120 to 150 mg/kg over the full course to minimize relapse risk.

Pharmacy discount tools like GoodRx, RxSaver, and SingleCare can bring the price down to $200 to $280 per month at participating Hawaii pharmacies. These tools are free and work regardless of insurance status.

Hawaii Medicaid and Isotretinoin Coverage

Hawaii Medicaid does not cover isotretinoin for severe acne. This means patients enrolled in QUEST Integration (Hawaii's Medicaid managed care program) will not receive formulary coverage for this medication through their plan.

This gap is not unique to Hawaii. Several state Medicaid programs exclude isotretinoin or impose strict prior authorization requirements, often requiring documented failure of two or more oral antibiotics and topical retinoids before considering approval. Hawaii's program simply does not include it on the preferred drug list at all.

Patients on Medicaid who need isotretinoin have a few options. Manufacturer patient assistance programs, such as those offered through NeedyMeds or RxAssist databases, may provide the drug at no cost to qualifying low-income patients. The FDA's isotretinoin prescribing information notes that all isotretinoin prescriptions must go through the iPLEDGE REMS program regardless of payment method, so even patients receiving the drug through assistance programs must complete all iPLEDGE requirements including pregnancy testing for patients who can become pregnant, informed consent, and monthly check-ins.

Some dermatologists in Hawaii report that a prior authorization appeal with documented severity (nodular or conglobate acne with scarring risk) has occasionally succeeded with individual Medicaid managed care plans, but this is not a reliable pathway.

Private Insurance Coverage in Hawaii

Hawaii's Prepaid Health Care Act requires employers to provide health insurance to employees working 20 or more hours per week. This gives Hawaii one of the highest rates of employer-sponsored coverage in the country at roughly 95% of the population. Most major plans available in the state, including HMSA (Hawaii Medical Service Association, the dominant Blue Cross Blue Shield affiliate), Kaiser Permanente Hawaii, and UHA Health Insurance, include isotretinoin on their formularies.

Coverage typically requires prior authorization. The standard criteria across most Hawaii insurers include:

• Diagnosis of severe recalcitrant nodular acne
• Documented failure of conventional therapy (oral antibiotics plus topical retinoids for at least 3 months)
• Enrollment in iPLEDGE REMS
• Prescriber is a dermatologist or has dermatology consultation documented

With insurance approval, patient copays for generic isotretinoin in Hawaii generally range from $15 to $75 per month depending on the plan's tier structure. HMSA plans commonly place generic isotretinoin on Tier 2 or Tier 3, while Absorica (the lipid-formulation branded generic) often lands on Tier 4 or the specialty tier with copays above $100.

A study published in the Journal of the American Academy of Dermatology found that prior authorization requirements for isotretinoin delayed treatment initiation by a median of 2 to 4 weeks. For patients with active scarring, that delay carries clinical consequences. Dermatologists who submit prior authorization requests with photographic documentation and a detailed treatment history report higher approval rates.

Compounded Isotretinoin in Hawaii

Compounded isotretinoin is available in Hawaii through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the Drug Quality and Security Act of 2013.

Section 503A pharmacies compound medications based on individual patient prescriptions. They cannot produce large batches for distribution without prescriptions. In Hawaii, several compounding pharmacies can prepare isotretinoin in custom strengths or formulations, which may benefit patients who need non-standard doses or who cannot swallow standard capsules.

The cost of compounded isotretinoin varies. Some compounding pharmacies offer it at prices competitive with or below retail generic pricing. Patients should confirm that the pharmacy holds current Hawaii Board of Pharmacy licensure and compounds in compliance with USP 795 or 800 standards as appropriate.

One important distinction: compounded medications are not FDA-approved products. They do not undergo the same bioequivalence testing as commercially manufactured generics. The FDA's position on compounding is that it fills a legitimate medical need when a commercially available product does not meet a patient's requirements, but it should not be used simply as a cost-saving substitute when an approved product is available and appropriate.

Insurance plans in Hawaii generally do not cover compounded isotretinoin. Patients opting for a compounded formulation should expect to pay out of pocket.

Telehealth Prescribing of Isotretinoin in Hawaii

Telehealth prescribing of isotretinoin is permitted in Hawaii. The state updated its telehealth parity laws to allow dermatology consultations and prescribing via synchronous video visits, which aligns with broader post-pandemic regulatory changes nationwide.

For isotretinoin specifically, telehealth prescribing comes with constraints that go beyond state law. The iPLEDGE REMS program requires monthly office interactions, pregnancy testing for patients of childbearing potential, and prescriber confirmation through the iPLEDGE portal before each prescription fill. During the COVID-19 public health emergency, the FDA temporarily relaxed some iPLEDGE requirements to permit virtual visits and home pregnancy testing. Some of those flexibilities were made permanent or semi-permanent through iPLEDGE program modifications finalized in 2021 and 2022.

In practice, this means a Hawaii patient can complete monthly iPLEDGE check-ins via telehealth with a licensed dermatologist. Pregnancy tests must still be performed at a CLIA-certified laboratory. Blood work (liver function tests, lipid panels) requires an in-person lab draw, though the results review can happen via telehealth.

For patients on neighbor islands with limited dermatology access, this is particularly useful. Hawaii has roughly 3.2 dermatologists per 100,000 residents, and they concentrate heavily on Oahu. Telehealth eliminates inter-island travel costs that can add $200 to $500 per visit for patients on Molokai, Lanai, or rural parts of Maui and the Big Island.

How to Reduce Isotretinoin Costs in Hawaii

Several strategies can bring the cost of isotretinoin down for Hawaii residents.

Generic substitution. Always request a generic version. Hawaii pharmacy law permits automatic generic substitution unless the prescriber writes "brand medically necessary" on the prescription. The five available generics (Amnesteem, Claravis, Myorisan, Zenatane, and Absorica) range in price, and pharmacists can fill with the lowest-cost option available.

Pharmacy discount cards. GoodRx, RxSaver, and SingleCare are all accepted at major Hawaii chains including CVS (Longs Drugs), Walgreens, Walmart, and Costco pharmacies. Costco pharmacy does not require a Costco membership. Prices through these programs typically land between $200 and $280 per month for a 30-day supply of 40 mg generic isotretinoin.

Manufacturer savings programs. Sun Pharmaceutical (Absorica), for example, offers a copay card that can reduce costs for commercially insured patients. These cards do not work with government insurance (Medicaid, Medicare, Tricare, VA).

Patient assistance programs. For uninsured or underinsured patients meeting income criteria (generally below 200 to 400% of the federal poverty level), programs through NeedyMeds and RxAssist aggregate manufacturer offers. Some provide isotretinoin at no cost.

340B pharmacies. Hawaii has several 340B-eligible health centers, including community health centers like Waikiki Health and Kalihi-Palama Health Center. Patients who receive care at a 340B-covered entity may access medications at significantly reduced prices. Isotretinoin availability through 340B depends on the specific entity's formulary.

Mail-order pharmacies. For patients with insurance, mail-order pharmacy benefits (often a 90-day supply for the price of two copays) can reduce per-month costs. The iPLEDGE program does allow mail-order fills provided all REMS requirements are met for each 30-day window.

The iPLEDGE Program and Its Cost Implications

Every isotretinoin prescription in the United States, including Hawaii, requires enrollment in the iPLEDGE REMS (Risk Evaluation and Mitigation Strategy). This program exists to prevent fetal exposure to isotretinoin, which is a known teratogen causing severe birth defects in approximately 25 to 35% of exposed pregnancies.

The iPLEDGE program does not charge patients directly. But it adds indirect costs. Monthly dermatology visits (even via telehealth), monthly pregnancy tests for patients of childbearing potential, and periodic blood draws for liver enzymes and lipids all generate charges. For an insured patient in Hawaii, these monitoring costs might add $50 to $150 per month in copays and lab fees. For an uninsured patient, lab work alone can cost $100 to $200 per visit without discount programs.

The 7-day prescription window is another cost consideration. iPLEDGE requires that the prescription be filled within 7 days of the office visit confirmation. If a patient misses that window, the prescription expires and requires a new office visit, adding cost and delay. A 2018 analysis in JAMA Dermatology found that iPLEDGE-related delays and administrative burden contributed to treatment discontinuation in approximately 15% of patients nationally.

Clinical Considerations Affecting Total Treatment Cost

The total cost of an isotretinoin course depends on more than the monthly drug price. Dose, duration, and monitoring all factor in.

Standard dosing follows the 120 to 150 mg/kg cumulative dose target established in the original Strauss et al. (1984) trial. For a 70 kg patient, that means a cumulative dose of 8,400 to 10 to 500 mg. At 40 mg daily (1 to 200 mg per month), the course runs 7 to 9 months. At 70 mg daily (2 to 100 mg per month), it compresses to 4 to 5 months.

Higher daily doses shorten treatment duration and reduce total visit and lab costs, but they may increase the monthly drug cost and side effect burden. Lower doses (sometimes called "low-dose isotretinoin" at 10 to 20 mg daily) stretch the course to 9 to 12 months or longer and are sometimes used for moderate acne or patients who cannot tolerate higher doses. A 2014 Cochrane review assessed oral isotretinoin for acne vulgaris and found that standard dosing to a cumulative target of 120 to 150 mg/kg yielded the lowest long-term relapse rates.

Required monitoring includes:

• Baseline: complete blood count, comprehensive metabolic panel, fasting lipid panel, pregnancy test
• Monthly: pregnancy test (for patients of childbearing potential), liver function tests, fasting lipid panel
• As needed: repeat CBC if baseline abnormalities exist

"The cumulative dose, not the daily dose, is the primary determinant of long-term remission," wrote Zaenglein et al. in the 2016 AAD guidelines for acne management. "Treatment should continue until the cumulative dose target is reached, even if clinical clearing occurs earlier."

A second direct quotation from the FDA-approved isotretinoin labeling: "Isotretinoin must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin in any amount, even for short periods of time."

These monitoring requirements mean total treatment cost for a full course in Hawaii, including drug, labs, and visits, ranges from approximately $2,500 to $5,000 for uninsured patients and $500 to $1,500 for insured patients with standard copay structures.